Bausch + Lomb and Clearside's Xipere Receive the US FDA's Approval for the Treatment of Macular Edema Associated with Uveitis
Shots:
- The approval is based on the P-III PEACHTREE trial to evaluate Xipere in 160 patients with macular edema associated with uveitis. The therapy is expected to be available in Q1'22
- The results showed that the greater proportion of patients treated with Xipere had achieved an improvement in BCVA (47% vs 16%) @24wks. Additionally, safety and efficacy data of Xipere had shown in multiple clinical studies
- Xipere is the 1st therapy to be available in the US & is designed to treat macular edema associated with uveitis via suprachoroidal administration using SCS Microinjector which has been developed by Clearside
Click here to read full press release/ article | Ref: PRNewswire | Image: LinkedIn
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com